Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards-Reference-Cited by-同舟云学术

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards

Published:2021-04 Issue:2 Volume:6 Page:100040
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Danesi R.,Fogli S.,Indraccolo S.,Del Re M.,Dei Tos A.P.,Leoncini L.,Antonuzzo L.,Bonanno L.,Guarneri V.,Pierini A.,Amunni G.,Conte P.

Funder

Gilead Sciences

Bayer

Teva Pharmaceutical Industries

Novartis

Sanofi Genzyme

Bristol-Myers Squibb

PharmaMar

AstraZeneca

Ipsen

Roche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference187 articles.

1. Agnostic-histology approval of new drugs in oncology: are we already there?;Hierro;Clin Cancer Res,2019

2. Drugging the ‘undruggable’ cancer targets;Dang;Nat Rev Cancer,2017

3. Emerging functions of the EGFR in cancer;Sigismund;Mol Oncol,2018

4. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget,2016

5. My Cancer Genome Vanderbilt-Ingram Cancer Center,2017

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On the discovered Cancer Driving Nucleotides (CDNs) –Distributions across genes, cancer types and patients;2024-09-04

2. On the discovered Cancer Driving Nucleotides (CDNs) –Distributions across genes, cancer types and patients;2024-09-04

3. Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways;Critical Reviews in Oncology/Hematology;2024-07

4. On the discovered Cancer Driving Nucleotides (CDNs) –Distributions across genes, cancer types and patients;2024-06-02

5. Particle uptake in cancer cells can predict malignancy and drug resistance using machine learning;Science Advances;2024-05-31